(function(){ var content_array=["

About Grunenthal<\/strong><\/p>\r\n

The Grunenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain treatment, its objective is to become the most patient-centric company and thus to be a leader in therapy innovation. Grunenthal is one of the last remaining five research-oriented pharmaceutical companies with headquarters in Germany which sustainably invests in research and development. The research and development costs amounted to a preliminary of about 26 percent of revenues in 2012. Grunenthal's research and development strategy concentrates on selected fields of therapy and state-of-the-art technologies. We are intensely focused on discovering new ways to treat pain better and more effectively, with fewer side-effects than current therapies. Altogether, the Grunenthal Group has affiliates in 26 countries worldwide. Grunenthal products are sold in more than 155 countries and today approx. 4,400 employees are working for the Grunenthal Group worldwide. In 2012, Grunenthal achieved preliminary revenues of EUR 973 mn. More information:http:\/\/www.grunenthal.com<\/a>.<\/p>\r\n

1 Pal M et al (2009). Vanilloid receptor antagonists: emerging class of novel anti-inflammatory agents for pain management. Curr Pharm Des 15:1008-26<\/p>\r\n

2 Dworkin RH, O'Connor AB, Backonja M, et al (2007). Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain;132:237-51<\/p>\r\n

3 Mick G et al (2012). What is localised neuropathic pain? A first proposal to characterise and define a widely used term. Pain manage 2(1), 71-77<\/p>\r\n

4 Woolf C et al (1999). Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet; 353:1959-64<\/p>\r\n

Contact:<\/strong> Jeanette Hubsch, Grunenthal Europe & Australia Phone: +49-241-569-1487, email: jeanette.huebsch@grunenthal.com<\/a><\/p>"]; $("#dvExtra").html(content_array[0]);})();